Article

Dr Jennifer Martin Discusses How Insomnia Has Evolved & Affects In Insurance Coverage

Conference|SLEEP: American Academy of Sleep Medicine and Sleep Research Society (APSS) Annual Meeting

In this video, Jennifer Martin, PhD, Assistant Professor, UCLA, David School of Medicine, shares her thoughts on how non-pharmacologic treatments for the management of insomnia has evolved over the past few years and how the increased use of behavioral treatments might affect insurance coverage.

In this video, Jennifer Martin, PhD, Assistant Professor, UCLA, David School of Medicine, shares her thoughts on how non-pharmacologic treatments for the management of insomnia has evolved over the past few years and how the increased use of behavioral treatments might affect insurance coverage.

This video was taken on June 3, 2013, at the Sleep 2013 Conference in Baltimore, MD.

Related Videos
Milind Desai, MD
Masanori Aikawa, MD
Neil Goldfarb, GPBCH
Mabel Mardones, MD.
Mei Wei, MD, an oncologist specializing in breast cancer at Huntsman Cancer Institute at the University of Utah.
Alexander Mathioudakis, MD, PhD, clinical lecturer in respiratory medicine at The University of Manchester
Screenshot of Susan Wescott, RPh, MBA
Screenshot of an interview with Adam Colborn, JD
Screenshot of an interview with James Chambers, PhD
Screenshot of an interview with Megan Ehret, PharmD
Related Content
Khadijah Breathett, MD
November 19th 2024

Community Investment, Engagement Are Essential to Fully Address Cardiovascular Health Disparities

Kyle Munz
Community-based researchers can teach clinicians a lot about how to best approach underserved populations disproportionately impacted by cardiovascular health complications.
Image of Managed Care Cast logo
August 29th 2023

The Importance of Examining and Preventing Atrial Fibrillation

Maggie L. Shaw
At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Latest From FINEARTS-HF: No Sex-Specific Differences in Finerenone Outcomes for Heart Failure
November 18th 2024

Latest From FINEARTS-HF: No Sex-Specific Differences in Finerenone Outcomes for Heart Failure

Kyle Munz
The FINEARTS-HF trial offered novel clinical insights as one of the few cardiovascular trials to feature such a great proportion of female participants.
Managed Care Cast.
June 28th 2022

Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions

Matthew Gavidia
On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Kerendia press photo | Image credit: Bayer
November 18th 2024

Benefits of Finerenone Similar in Women and Men, Analysis Finds

Mary Caffrey
Follow-up results for the FINEARTS-HF trial focused on specific results for women and men, hyperkalemia risk, and an analysis of the elements of its composite end point.
Alexander T. Sandhu, MD, MS | Image credit: Standford University
November 17th 2024

Education, Feedback Boosts Pharmacists’ HF Medication Rates

Mary Caffrey
Lead study author Alexander T. Sandhu, MD, MS, of Stanford said the team will evaluate behavior to understand the results.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo